Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025)

Spero Therapeutics filings provide 2 years of Asset Writedowns and Impairment readings, the most recent being $600000.0 for Q3 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $600000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $600000.0, a 88.69% decrease, with the full-year FY2025 number at $587000.0, changed N/A from a year prior.
Asset Writedowns and Impairment hit $600000.0 in Q3 2025 for Spero Therapeutics, down from $5.3 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $5.3 million in Q3 2023 to a low of $600000.0 in Q3 2025.